Technology | July 01, 2015

American College of Cardiology Develops Statin Intolerance App

App to guide clinicians in treating patients with muscle pain during statin therapy

ACC, Statin Intolerance App, statin therapy, muscle symptoms, pain

July 1, 2015 - The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the process of managing and treating patients who report muscle symptoms while on statin therapy.

Although muscle symptoms may occur while on statin therapy, true statin intolerance is uncommon. Because of the abundance of research showing the benefits of statin therapy for heart disease risk reduction, clinicians should partner with patients in determining if the patient is truly statin-intolerant. Patients reporting muscle symptoms while on a statin with should be managed and treated with cycles of discontinuation and rechallenge to identify a tolerated statin and dose.

The ACC Statin Intolerance App is designed to help guide this process. Using the app, clinicians can answer questions to evaluate possible intolerance to a patient's current statin prescription, follow steps to manage and treat a patient who reports muscle symptoms on a statin, and compare statin characteristics and drug interactions to inform management of LDL, or "bad" cholesterol, related risks. The app may also be helpful as a resource and teaching tool for students, trainees and clinicians less familiar with standard guidance and protocols for addressing statin intolerance.

The app was developed as part of the ACC's LDL: Address the Risk Initiative, a quality program designed to improve patient outcomes by increasing awareness of the gaps in managing cholesterol, including the importance of managing the risks of high LDL. The app is also part of a larger and ongoing effort by the college to help its members and other clinicians translate guidelines and other clinical policy statements into practice at the point of care. Content in the app was derived from the ACC/AHA's (American Heart Association) 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults as well as prescribing information from each statin.

Financial support for the LDL: Address the Risk Initiative was provided by Amgen Inc. All of the content was independently developed with no sponsor involvement.

The ACC Statin Intolerance App is available for free, in both Web and mobile versions, on the ACC website or in the iTunes or Google Play app stores.

For more information:

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init